APSR2026-166

Yes
Late-Breaking
Submitted
Oral Presentation
AO06-002
 
 
https://storage.unitedwebnetwork.com/files/1285/1212073-46903-APSR-166_439737.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Naoki Watanabe * Kagawa University Department of Internal Medicine, Hematology, Rheumatology and Respiratory Medicine Kagawa Japan
Yasuhiro Ohara - Kagawa University Department of Internal Medicine, Hematology, Rheumatology and Respiratory Medicine Kagawa Japan
Takuya Inoue - Kagawa University Department of Internal Medicine, Hematology, Rheumatology and Respiratory Medicine Kagawa Japan
Hirokazu Ogino - Tokushima University Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima Japan
Hiroshi Nokihara - Tokushima University Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima Japan
Yasuhiko Nishioka - Tokushima University Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences Tokushima Japan
Yutaka Ueda - Kagawa Prefectural Central Hospital Department of Respiratory Medicine Kagawa Japan
Hiroshi Miyawaki - Kagawa Prefectural Central Hospital Department of Respiratory Medicine Kagawa Japan
Hirohisa Ichikawa - KKR Takamatsu Hospital Department of Respiratory Medicine Kagawa Japan
Tomoya Ishii - Takinomiya General Hospital Department of Respiratory Medicine Kagawa Japan
Gen Masuda - Sakai City Medical Center Department of Respiratory Medicine Osaka Japan
Hiroaki Muguruma - Takamatsu Red Cross Hospital Department of Respiratory Medicine Kagawa Japan
Hiroyuki Nakamura - Sakaide City Hospital Department of Respiratory Medicine Kagawa Japan
Naoki Nishimoto - Hokkaido University Hospital Data Science Center, Institute of Health Science Innovation for Medical Care Hokkaido Japan
Nobuhiro Kanaji - Kagawa University Department of Internal Medicine, Hematology, Rheumatology and Respiratory Medicine Kagawa Japan
Presenting Author Details
Naoki
Watanabe
watanabe.naoki@kagawa-u.ac.jp
+819044293813
41-50
Japan
Original Research
Primary Prophylaxis with Pegfilgrastim for Febrile Neutropenia in Patients with Non-Small Cell Lung Cancer Receiving Docetaxel and Ramucirumab: A Randomized Controlled Trial
Maximum 25 words
Abstract Content
The combination of docetaxel (DTX) and ramucirumab (RAM) is a standard second-line treatment for advanced non-small cell lung cancer (NSCLC). However, this regimen is associated with a high incidence of febrile neutropenia (FN), reported between 16% and 34% in clinical trials. This study aimed to evaluate the efficacy and safety of primary prophylaxis with pegfilgrastim in patients receiving DTX and RAM.
In this multicenter, randomized, open-label trial, patients with advanced NSCLC were assigned to either Group A (reactive G-CSF administration upon onset of neutropenia or fever) or Group B (primary prophylaxis with 3.6 mg pegfilgrastim on Day 2–4). Patients received DTX (60 mg/m²) and RAM (10 mg/kg) every 3 weeks. The primary endpoint was the incidence of FN during the first cycle.
A total of 130 evaluable patients (Group A, n=61; Group B, n=69) were analyzed. The incidence of FN was 34.4% (21/61) in Group A and 14.5% (10/69) in Group B. Primary prophylaxis with pegfilgrastim significantly reduced the risk of FN. Notably, a higher proportion of patients in Group B were able to proceed to the second treatment cycle without docetaxel dose reduction compared to Group A. Regarding safety, bone pain was more frequent in Group B (17.1% vs 3.2% in Group A), yet it was mostly mild, with only one patient experiencing Grade 3 bone pain. No significant differences were observed between the two groups in the incidence of other adverse events, including stomatitis, fatigue, and anorexia.
Primary prophylaxis with pegfilgrastim significantly lowered the incidence of FN in NSCLC patients undergoing DTX and RAM therapy compared to reactive G-CSF support. These findings support the routine use of prophylactic pegfilgrastim with this chemotherapy regimen to improve treatment safety.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Non-small cell lung cancer, Febrile neutropenia, Pegfilgrastim
maximum 3 keywords and no abbreviations, separated by commas
 
291